GBC has proudly received the 2025 Taiwan Excellence Award for its fully automated cell sorting system, CellBio™ FX10. This innovative system employs cutting-edge technology to efficiently isolate and recover circulating tumor cells (CTC) from blood, delivering high sensitivity and specificity. It provides a reliable, precise analytical tool for cancer research and clinical diagnostics, enhancing tumor monitoring capabilities. GBC demonstrates its leadership in the medical and precision instrumentation fields, continuously advancing the development of precision medicine.
Established in 1993, the Taiwan Excellence Award selects products each year through a rigorous evaluation process based on four main criteria: "R&D," "Design," "Quality," and "Marketing," while also considering the "Made in Taiwan" factor. Products awarded embody "innovative value," serving as exemplars for Taiwan's industries. This award for GBC highlights the company’s R&D strengths and technological prowess, aligning with the Taiwan Excellence Award's emphasis on product innovation.
The GBC CellBio™ system for detecting circulating tumor cells (CTC) leverages the proprietary iFiltration™ membrane separation technology. This technique allows for the extraction of circulating tumor cells from a small blood sample, achieving a capture rate of over 90%. This technology aids doctors in the timely detection and tracking of cancer cells in a non-invasive sampling process, enabling earlier treatment and more accurate therapeutic options for cancer patients.
Established in 1993, the Taiwan Excellence Award selects products each year through a rigorous evaluation process based on four main criteria: "R&D," "Design," "Quality," and "Marketing," while also considering the "Made in Taiwan" factor. Products awarded embody "innovative value," serving as exemplars for Taiwan's industries. This award for GBC highlights the company’s R&D strengths and technological prowess, aligning with the Taiwan Excellence Award's emphasis on product innovation.
The GBC CellBio™ system for detecting circulating tumor cells (CTC) leverages the proprietary iFiltration™ membrane separation technology. This technique allows for the extraction of circulating tumor cells from a small blood sample, achieving a capture rate of over 90%. This technology aids doctors in the timely detection and tracking of cancer cells in a non-invasive sampling process, enabling earlier treatment and more accurate therapeutic options for cancer patients.
){kind=link}